摘要
目的:研究超大剂量顺铂治疗晚期卵巢癌的临床疗效和可行性。方法:对23例FIGO期别≥c的晚期卵巢癌施行超大剂量顺铂(120～150mg/m2)化疗,采用David法计算顺铂的剂量强度、UICC和WHO标准评定临床疗效和毒副反应。结果:共进行100疗程化疗,顺铂剂量强度(DI)3.08±0.92,总剂量强度(TDI)12.08±3.92,临床完全反应率60.86%,有效率65.22%,顺铂DI、TDI和近期疗效无关(P>0.05)。23例中无一例因化疗毒副反应死亡,但出现剂量限制毒性21疗程。初治病例中位生存14个月,无瘤中位生存13个月。结论:超大剂量顺铂治疗晚期卵巢癌难以达到计划顺铂剂量强度。
Objectives:To study effectiveness and acceptability of treatment with superhigh dose cispltin in advanced ovarian cancer.Methods:23 cases of advanced ovarian cancer(FIGO≥Ⅱc)were treated with superhigh dose cispltin(120～150mg/m 2).Using Davids method,cispltin dose intensity was calculated.Clinical response rate and toxicity were evaluated according to UICC and WHO criteria.Results:100 courses chemotherapy were performed,average 4.35 courses percase.Cispltin dose intennsity(DI)was 3.08±0.92,and total dose intesity(TDI)was 12.08±3.92.The objective response rate was 65.22%with 60.86%complete responses.No signicant correlation was found between DI and TDI of cispltin and clinical responses( P >0.05).Seven patients had finished or were persisting in finishing planned regimes.Chemotherapy were given at 4 week intervals in 53.94% courses.No case died of toxicity of cispltin.Dose limited toxicity were observed in 21 courses,mainly gastrointestinal,nervous and renal toxicity.Medial survival for primary treated patients was 14 months,disease free medial survival was 13 months.Conclusions:Planned cispltin dose intensity is difficult to be obtained in advanced ovarian cancer treated with superhigh dose cispltin.In the human being,increasing cispltin doses may be not improve clinical effect.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2000年第1期37-38,共2页
Journal of Practical Obstetrics and Gynecology
